[Use of miramistin for the treatment of patients with odontogenic phlegmons in the maxillofacial area].
In experimental and clinical conditions the use of miramystin (0.1% solution and liniment) was validated for complex treatment of patients with odontogenic maxillofacial phlegmons (110 patients with mild, moderate and severe inflammation). Significant efficacy of a wide spectrum antiseptic (miramystin) and laser fluorescent diagnostic method for achievement of objective assessment of the treatment of patients with phlegmons in maxillofacial area is shown. The disease duration (time from its onset till discharge from the hospital) varied from 8.2 to 24.1 days depending upon the degree of severity of the inflammatory process versus 13.7 to 30.4 days in controls, respectively. The developed treatment-and-diagnostic methodology is recommended for wide clinical practice.
Bazhanov
N N
NN
Aleksandrov
M T
MT
Cherkesov
I V
IV
D000287:Administration, Topical; D000328:Adult; D001548:Benzalkonium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D002481:Cellulitis / Q000175:diagnosis / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007571:Jaw Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome
D001548:Benzalkonium Compounds; C058048:miramistin